Hepatitis
Pregnancy And Hepatitis B
There is a big question raised when thinking about B: can infants risk to loose their immunoprophylaxis if breast feed by mothers that carry the B virus? This is one of the most often asked questions when new mothers with B have children.
Well the answer is no. There is no risk for a mother with B to breast feed his child. The infant will not suffer from any negative influences when the response of the anti B is concerned. Many tests have been made concerning mothers that have B virus and have to breast feed their new- born.
All the results have shown that there us no big difference when immunoprophylaxis failure is concerned
in children that have been breast feed by their mothers which carry the B virus and the babies that were feed by bottle. Another question asked was whether there was a bigger risk of transmitting B to the infant if breastfeed by the mother that carry the B virus. The answer was given after some studies made by doctors. If the infant is vaccinated against B and taking into consideration B globulin, the infant that is breast feed by his B carrying mother is not at more risk of getting B from her.
There is also the problem of infection with B virus of the foetus. The answer is very simple. Even if the mother has the B virus, the infection with in the uterus may be stopped by injections. This method does not have any side- effects and can protect the foetus from B virus.
Another matter that we must take into consideration when talking about B is the vaccine. The question is can pregnant women get vaccinated against B? And the answer is very satisfying, yes they can. This liver problem, B in pregnancies can not be associated with an increased rate of abortion or congenital malformation. However, there is a matter to take into consideration if pregnant and having B virus. If this virus is acquired in your last trimester, your child might be born early. Another problem is that more than half of the women that contact B virus in their last days of pregnancy are more than likely to transmit the virus to their children.
We strive to provide only quality information, so
if
there is a specific topic related to hepatitis
that you would
like us to cover, please contact us at any time.
And again, thank you to those contributing daily to
our Hepatitis
Website, especially
regarding "hepatitis b".
If you can't find the
Hepatitis information you are looking for?
Try Google Search
Immune Dysregulation in Hepatitis C Patients With or Without Arthritis
<b>Condition</b>: Hepatitis C Patients<br/><b>Intervention</b>: <br/><b>Sponsors</b>: The Center for Rheumatic Disease, Allergy, & Immunology; St Luke's Hospital<br/><b>Recruiting</b> - verified September 2010
A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon? in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
<b>Conditions</b>: Chronic Hepatitis C Infection; Genotype 1<br/><b>Interventions</b>: Drug: recombinant variant of interferon-alpha 2b; Drug: Peginterferon alfa-2a<br/><b>Sponsor</b>: HanAll BioPharma Co., Ltd.<br/><b>Not yet recruiting</b> - verified September 2010
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
<b>Conditions</b>: Hepatitis C Virus; Chronic Liver Disease; Viral Hepatitis; Therapeutic Uses; Antiviral Agents<br/><b>Intervention</b>: Drug: peginterferon plus ribavirin<br/><b>Sponsors</b>: Azienda Ospedaliera di Padova; Regione Veneto; University of Padua<br/><b>Completed</b> - verified September 2010
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
<b>Condition</b>: HCV Infection<br/><b>Interventions</b>: Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo<br/><b>Sponsor</b>: Gilead Sciences<br/><b>Recruiting</b> - verified August 2010
Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus
<b>Conditions</b>: Hepatitis C; Liver Transplant<br/><b>Intervention</b>: Drug: IV interferon<br/><b>Sponsors</b>: Carolinas Healthcare System; American College of Gastroenterology<br/><b>Enrolling by invitation</b> - verified August 2010
|
